PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
A proportion of prostate cancer (PCa) patients develop relapse following curative local
treatment. Regional nodal recurrence is an emerging clinical situation since the introduction
of new molecular imaging methods in the restaging of recurrent prostate cancer. More
specifically, a subgroup of these patients is being diagnosed with a recurrence confined to
the regional lymph nodes and limited in number (oligorecurrence) using choline or PSMA
PET-CT. As there are no specific treatment recommendations for these type of patients,
different treatment approaches are currently used, mostly focusing on local ablative
treatments using radiotherapy or surgery. These treatments are coined metastasisdirected
therapy (MDT). MDT in combination with or without temporary ADT could delay the subsequent
risk of progression, and even cure limited regional nodal recurrences. Consequently, lifelong
palliative ADT, with its toxicity and excess in non-cancer mortality might be postponed.
The proposed trial randomizes patients with oligorecurrent nodal prostate cancer following
primary PCa treatment to either metastasis-directed therapy (MDT) (salvage lymph node
dissection, sLND or stereotactic body radiotherapy, SBRT) or MDT plus whole pelvis
radiotherapy (WPRT: 45 Gy in 25 fractions).
Phase:
Phase 2
Details
Lead Sponsor:
University Ghent
Collaborators:
Geneva University Hospital University Hospital, Geneva